A new AI-driven way of identifying how patients with advanced bowel cancer will respond to a drug that was recently introduced by the NHS has been announced.
Researchers at London’s Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have developed the method with the goal of sparing potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers.
